Compatibility study of rivaroxaban and its pharmaceutical excipients

被引:19
作者
Ding, Ting [1 ]
Chen, Lan [1 ]
Zhai, Li-Hai [1 ,3 ]
Fu, Yan [2 ]
Sun, Bai-Wang [1 ]
机构
[1] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China
[2] Southeast Univ, Nanjing 211189, Jiangsu, Peoples R China
[3] Shandong Lunan Pharmaceut Grp Co Ltd, Linyi 276000, Shandong, Peoples R China
关键词
Rivaroxaban; Compatibility; XRPD; DSC; FACTOR XA INHIBITOR;
D O I
10.1007/s10973-017-6412-3
中图分类号
O414.1 [热力学];
学科分类号
摘要
Rivaroxaban is an oral direct Factor Xa inhibitor to treat thrombus. The aim of this study is to investigate the drug-excipient compatibility between rivaroxaban tablet and pharmaceutical excipients by a combination of thermal and spectroscopic methods. Differential scanning calorimetry (DSC) is the most important technique to evaluate the compatibility. In addition, X-ray powder diffraction (XRPD) is a complementary technique to explain the DSC result and exclude relevant interaction. On the basis of DSC curves about rivaroxaban and excipient and mixture (1:1, w/w), the rivaroxaban was considered to be compatible with the most excipients (microcrystalline cellulose, lactose, hydroxyl propyl methyl cellulose, magnesium stearate). Meanwhile, the XRPD studies also showed the compatibility of rivaroxaban and pharmaceutical excipients, especially for the sodium lauryl sulfate. Overall, the compatibility of the excipients with rivaroxaban was assessed successfully by DSC and XRPD, and the formulations developed using the compatible excipient were found to be stable.
引用
收藏
页码:1569 / 1573
页数:5
相关论文
共 18 条
  • [1] [Anonymous], 2015, Excipient Applications in Formulation Design and Drug Delivery
  • [2] Thermal analysis of the antiretroviral zidovudine (AZT) and evaluation of the compatibility with excipients used in solid dosage forms
    Araújo, AAS
    Storpirtis, S
    Mercuri, LP
    Carvalho, FMS
    dos Santos, M
    Matos, JR
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) : 303 - 314
  • [3] Gamini V, 2011, CN, Patent No. [CN102292332 A, 102292332]
  • [4] Study of stability and drug-excipient compatibility of estradiol and pharmaceutical excipients
    Gao, Rui
    Jin, Yi
    Yang, Qing-Yi
    Sun, Bai-Wang
    Lin, Jun
    [J]. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2015, 120 (01) : 839 - 845
  • [5] Compatibility of medroxyprogesterone acetate and pharmaceutical excipients through thermal and spectroscopy techniques
    Gao, Rui
    Sun, Bai-Wang
    Lin, Jun
    Gao, Xiao-Li
    [J]. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2014, 117 (02) : 731 - 739
  • [6] Groom Nanboge A, NEW CRYSTAL FORMS AM
  • [7] Grunenberg A, 2013, US, Patent No. [US 8466280 B2, 8466280B2]
  • [8] Kandarapu R, 2001, STP PHARMA SCI, V11, P449
  • [9] Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Zuehlsdorf, Michael
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09) : 981 - 990
  • [10] Li DX, 2014, CN, Patent No. [CN104211693A, 104211693A]